Dermatology

This site is intended for healthcare professionals only

Login Register

MD Brand Connect
Webinars
Vaccine Hub
MDTV
Fact Check
Health Dialogues

Medical News & Guidelines
Health news
Fact Check
AYUSH
State News
Medical Education
Industry
MDTV

This site is intended for healthcare professionals only

Login Register

LoginRegister

Home
Medical news & Guidelines
Health news
Fact Check
AYUSH
State News
Medical Education
Industry

Ruchika Sharma

Ruchika Sharma joined Medical Dialogue as an Correspondent for the Business Section in 2019. She covers all the updates in the Pharmaceutical field, Policy, Insurance, Business Healthcare, Medical News, Health News, Pharma News, Healthcare and Investment. She has completed her B.Com from Delhi University and then pursued postgraduation in M.Com. She can be contacted at editorial@medicaldialogues.in Contact no. 011-43720751

Home

Ruchika Sharma

Articles By : Ruchika Sharma

Sanofi Gets CDSCO Panel Nod to Update Prescribing Information for Xenpozyme

Sanofi considers listing consumer unit late next year

Ruchika Sharma30 Oct 2023 2:30 PM IST

New Delhi: Sanofi has mapped out a separate listing of its consumer healthcare business from the fourth quarter of next year, the French drugmaker...

Natco Pharma gets 7 USFDA observations for Kothur Pharma Division

Dr Reddy's Labs gets 10 USFDA observations for Bachupally facility

Ruchika Sharma30 Oct 2023 1:30 PM IST

Hyderabad: Dr Reddy's Labs has recently announced that the United States Food & Drug Administration (USFDA) has competed an inspection with ten...

Sun Pharma Told to Revise Delafloxacin Phase III Trial Protocol

Sun Pharma to now offer Desidustat, first oral treatment for CKD-associated anaemia in India under brand Rytstat

Ruchika Sharma30 Oct 2023 12:50 PM IST

Mumbai: Strengthening its position in the chronic kidney disease space, Sun pharma is now going to offer Desidustat, the first-of-its-kind oral...

SPARC concludes enrolment in global Phase 2 study of Vodobatinib in early Parkinson's disease

Ruchika Sharma30 Oct 2023 11:30 AM IST

Vodobatinib is a potential first-in-class, highly selective and brain penetrating c-Abl inhibitor.

Strides Pharma Science posts consolidated net loss of Rs 149 crore in Q2

Ruchika Sharma30 Oct 2023 10:00 AM IST

New Delhi: Strides Pharma Science has reported a consolidated net loss of Rs 149 crore for the second quarter ended September 30, 2023.The drug firm...

Strides Pharma Science Acetaminophen and Ibuprofen Tablets

Strides to sell manufacturing facility in Singapore for Rs 125 crore

Ruchika Sharma29 Oct 2023 4:00 PM IST

"Proceeds from the transaction will be utilized for debt reduction," Strides stated.

No casual link found between GLP-1 drugs like Novo Nordisk Ozempic, thyroid cancer: EMA

Ruchika Sharma29 Oct 2023 12:30 PM IST

The European Medicines Agency (EMA) has said its safety panel did not find a causal link between popular GLP-1 drugs such as Novo...

USFDA warns against use of 26 over-the-counter eye drop products

Ruchika Sharma29 Oct 2023 11:30 AM IST

Bengaluru: The U S. Food and Drug Administration has issued a warning to consumers to not purchase or use certain eye drops from several major brands...

Venus Remedies gets market nod for Bleomycin 15000 IU in UK

Ruchika Sharma29 Oct 2023 10:00 AM IST

Mumbai: Venus Remedies has announced receipt of market authorization in the United Kingdom for Bleomycin 15,000 IU Powder for Solution for...

Gujarat: Fake antibiotic drugs, abortion-inducing medicines worth Rs 40 lakh seized

Ruchika Sharma28 Oct 2023 2:30 PM IST

Ahmedabad: Fake antibiotic drugs and medicines used to induce abortion worth nearly Rs 40 lakh have been seized from two different locations in...

CDSCO Panel Directs Abbott to Incorporate New Safety, Follow-up Measures in Clarithromycin Study

After USFDA warning, Abbott Labs to stop sales of Similac Probiotic Tri-Blend product

Ruchika Sharma28 Oct 2023 1:30 PM IST

"The product is an unapproved new drug and an unlicensed biological product being sold in violation" of regulations, the FDA said about Abbott's...

Dr Reddys Foils Email Spoofing Scam, Rs 2.16 Cr Recovered by Bengaluru Police

Dr Reddy's Labs PAT rises 33 percent to Rs 1482 crore in Q2

Ruchika Sharma28 Oct 2023 1:30 PM IST

Hyderabad: Dr Reddy's Laboratories has reported a 33.02 per cent increase in consolidated profit after tax at Rs 1,482.2 crore in the second quarter...

Powered By: Hocalwire

X

We use cookies for analytics, advertising and to improve our site. You agree to our use of cookies by continuing to use our site. To know more, see our Cookie Policy and Cookie Settings.Ok